Business
Eli Lilly shares plunged about 14% in midday trading Thursday after the company reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blo? [+373 chars]
Leave A Comment
Comments
No comments yet. Be the first to comment!
